New agonist- and antagonist-based treatment approaches for advanced prostate cancer (Q38042768)

27 August 2017

title

New agonist- and antagonist-based treatment approaches for advanced prostate cancer (English)

1 reference

27 August 2017

1 reference

Y Xu

1

1 reference

27 August 2017

Y F Jiang

series ordinal

2

1 reference

27 August 2017

B Wu

series ordinal

3

1 reference

27 August 2017

publication date

1 January 2012

1 reference

Journal of International Medical Research

27 August 2017

published in

1 reference

27 August 2017

volume

40

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

1217-1226

1 reference

27 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Prospective study of sex hormone levels and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Molecular genetics of prostate cancer: new prospects for old challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

History of prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Prostate cancer management: (1) an update on localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Gonadotropin-releasing hormone and its analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Peptide analogs in the therapy of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

The current state of hormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Testosterone surge: rationale for gonadotropin-releasing hormone blockers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Role of bombesin-related peptides in the control of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Neuroendocrine cells in tumour growth of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Octreotide in the management of hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: Results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Somatostatin analogue inhibits the mobility of prostate carcinoma cells: A new therapeutic method for advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001204000401

10.1177/147323001204000401

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference